Acumen Diagnostics' PCR capabilities to tackle Omicron COVID-19 variant
Dec 03, 2021 14:00 HKT |  |
|
中国抗体公布旗舰产品SM03完成在中国III期临床试验招募
Nov 30, 2021 20:52 HKT |  |
|
中國抗體公佈旗艦產品SM03完成在中國III期臨床試驗招募
Nov 30, 2021 20:51 HKT | |
|
SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03
Nov 30, 2021 20:50 HKT | |
|
Jacobson Pharma Announces FY2022 Interim Results
Nov 26, 2021 19:39 HKT |  |
|
SinoMab Was Invited to Attend the Inaugural Asia Summit on Global Health
Nov 26, 2021 18:26 HKT | |
|
휴머니젠, 영국흉부학회 2021년도 동계 회의에 접수된 초록 발표
Nov 26, 2021 16:00 HKT |  |
|
Inaugural Asia Summit on Global Health successfully explores healthcare landscape
Nov 25, 2021 20:00 HKT |  |
|
中国抗体受邀出席首届亚洲医疗健康高峰论坛
Nov 25, 2021 18:28 HKT | |
|
中國抗體受邀出席首屆亞洲醫療健康高峰論壇
Nov 25, 2021 18:27 HKT | |
|
Inaugural Asia Summit on Global Health opens today
Nov 24, 2021 18:00 HKT | |
|
行动基因与善觅宣布合并 展现香港医疗科技世界级潜力
Nov 22, 2021 16:59 HKT |  |
|
行動基因與善覓宣佈合併 展現香港醫療科技世界級潛力
Nov 22, 2021 16:58 HKT | |
|
ACT Genomics and Sanomics Merge to Unleash Hong Kong's Global Potential in Healthcare Technology
Nov 22, 2021 16:57 HKT | |
|
휴머니젠, 3분기 및 2021년 9월 30일 종결되는 9개월간의 재무 결과 보고 및 기업보고서 발표
Nov 22, 2021 11:00 HKT | |
|
冠科美博（Apollomics）Uproleselan 注射液（APL-106）用于治疗复发或难治性急性髓系白血病的中国 III 期临床试验第一例受试者成功入组
Nov 22, 2021 10:42 HKT |  |
|
冠科美博（Apollomics）Uproleselan 注射液（APL-106）用於治療復發或難治性急性髓系白血病的中國 III 期臨床試驗第一例受試者成功入組
Nov 22, 2021 10:41 HKT | |
|
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
Nov 22, 2021 10:40 HKT | |
|
휴머니젠, 급성 이식편대 숙주병을 대상으로 렌질루맙의 효과 평가를 위한 임상 연구 협력 발표
Nov 22, 2021 10:00 HKT | |
|
重磅！B细胞CD22单抗SM03治疗类风湿关节炎临床研究结果最新公布！
Nov 18, 2021 19:11 HKT | |
|